Citations

Mayo Clinic

Showing 10 of 108602 citations.

Long‐term quality of life after treatment in sinonasal malignancy: A prospective, multicenter study
Maoz, Sabrina L. , Hwang, Peter H. , Fleseriu, Cara M. , Chan, Erik P., Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Lazor, Jillian W. , Nabavizadeh, Ali , Adappa, Nithin D. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Suh, Jeffrey D. , Wang, Marilene B. , Sim, Myung‐Shin , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Beswick, Daniel , Hwang, Peter H , Maoz, Sabrina L , Choby, Garret , Chan, Erik, Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Lee, Jivianne K., Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Beswick, Daniel M.

International Forum of Allergy & Rhinology | April 21, 2023 | Volume: 13 | Issue: 11 | Pages: 2030-2042

10.1002/alr.23171 | PMID 37082883 Get It

AbstractBackgroundQuality of life (QOL) for individuals with sinonasal malignancy (SNM) is significantly under‐studied, yet it is critical for counseling and may impact treatment. In this study we evaluated how patient, treatment, and disease factors impact sinonasal‐specific and generalized QOL using validated metrics in a large cohort over a 5‐year posttreatment time frame.MethodsPatients with SNM who underwent definitive treatment with curative intent were enrolled in a prospective, multisite, longitudinal observational study. QOL was assessed using the 22‐item Sino‐Nasal Outcome Test (SNOT‐22) and University of Washington Quality of Life Questionnaire (UWQOL) instruments at pretreatment baseline and multiple follow‐ups through 5 years posttreatment. Multivariable modeling was used to determine demographic, disease, and treatment factors associated with disease‐specific and generalized physical and social/emotional function QOL.ResultsOne hundred ninety‐four patients with SNM were analyzed. All QOL indices were impaired at pretreatment baseline and improved after treatment. SNOT‐22 scores improved 3 months and UWQOL scores improved 6 to 9 months posttreatment. Patients who underwent open compared with endoscopic tumor resection had worse generalized QOL (p < 0.001), adjusted for factors including T stage. Pterygopalatine fossa (PPF) involvement was associated with worse QOL (SNOT‐22, p < 0.001; UWQOL Physical dimension, p = 0.02). Adjuvant radiation was associated with worse disease‐specific QOL (p = 0.03). Neck dissection was associated with worse generalized physical function QOL (p = 0.01). Positive margins were associated with worse generalized social/emotional function QOL (p = 0.01).ConclusionDisease‐specific and generalized QOL is impaired at baseline in patients with SNM and improves after treatment. Endoscopic resection is associated with better QOL. PPF involvement, adjuvant radiation, neck dissection, and positive margins were associated with worse QOL posttreatment.
Leveraging Exosomes as the Next-Generation Bio-Shuttles: The Next Biggest Approach against Th17 Cell Catastrophe
Samarpita, Snigdha , Li, Xiaogang

International Journal of Molecular Sciences | April 21, 2023 | Volume: 24 | Issue: 8 | Pages: 7647

10.3390/ijms24087647 | PMID 37108809 Get It

In recent years, the launch of clinical-grade exosomes is rising expeditiously, as they represent a new powerful approach for the delivery of advanced therapies and for diagnostic purposes for various diseases. Exosomes are membrane-bound extracellular vesicles that can act as biological messengers between cells, in the context of health and disease. In comparison to several lab-based drug carriers, exosome exhibits high stability, accommodates diverse cargo loads, elicits low immunogenicity and toxicity, and therefore manifests tremendous perspectives in the development of therapeutics. The efforts made to spur exosomes in drugging the untreatable targets are encouraging. Currently, T helper (Th) 17 cells are considered the most prominent factor in the establishment of autoimmunity and several genetic disorders. Current reports have indicated the importance of targeting the development of Th17 cells and the secretion of its paracrine molecule, interleukin (IL)-17. However, the present-day targeted approaches exhibit drawbacks, such as high cost of production, rapid transformation, poor bioavailability, and importantly, causing opportunistic infections that ultimately hamper their clinical applications. To overcome this hurdle, the potential use of exosomes as vectors seem to be a promising approach for Th17 cell-targeted therapies. With this standpoint, this review discusses this new concept by providing a snapshot of exosome biogenesis, summarizes the current clinical trials of exosomes in several diseases, analyzes the prospect of exosomes as an established drug carrier and delineates the present challenges, with an emphasis on their practical applications in targeting Th17 cells in diseases. We further decode the possible future scope of exosome bioengineering for targeted drug delivery against Th17 cells and its catastrophe.
Ulnar Nerve Transposition Is Justified in the Treatment of Distal Humerus Fracture
Barlow, Jonathan D. , Barlow, Jonathan

Journal of Orthopaedic Trauma | April 21, 2023 | Volume: 37 | Issue: 5 | Pages: e232-e233

10.1097/bot.0000000000002588 | PMID 37081697 Get It

Utilization of Circulating Tumor Cells in the Management of Solid Tumors
Kurniali, Peter C., Storandt, Michael H. , Jin, Zhaohui , Jin, Zhaohui

Journal of Personalized Medicine | April 21, 2023 | Volume: 13 | Issue: 4 | Pages: 694

10.3390/jpm13040694 | PMID 37109080 Get It

Circulating tumor cells (CTCs) are tumor cells shed from the primary tumor into circulation, with clusters of CTCs responsible for cancer metastases. CTC detection and isolation from the bloodstream are based on properties distinguishing CTCs from normal blood cells. Current CTC detection techniques can be divided into two main categories: label dependent, which depends upon antibodies that selectively bind cell surface antigens present on CTCs, or label-independent detection, which is detection based on the size, deformability, and biophysical properties of CTCs. CTCs may play significant roles in cancer screening, diagnosis, treatment navigation, including prognostication and precision medicine, and surveillance. In cancer screening, capturing and evaluating CTCs from peripheral blood could be a strategy to detect cancer at its earliest stage. Cancer diagnosis using liquid biopsy could also have tremendous benefits. Full utilization of CTCs in the clinical management of malignancies may be feasible in the near future; however, several challenges still exist. CTC assays currently lack adequate sensitivity, especially in early-stage solid malignancies, due to low numbers of detectable CTCs. As assays improve and more trials evaluate the clinical utility of CTC detection in guiding therapies, we anticipate increased use in cancer management.
Pragmatic evaluation of events and benefits of lipid lowering in older adults ( PREVENTABLE ): Trial design and rationale
Joseph, Jacob , Pajewski, Nicholas M. , Dolor, Rowena J , Sellers, Mary Ann, Perdue, Letitia , Peeples, Sheronda R., Henrie, Adam M., Woolard, Nancy , Benziger, Catherine P. , Mixon, Amanda S. , VanWormer, Jeffrey J. , Chatterjee, Ranee , Newby, L. Kristin , Cicek, Mine , Williams, Neely , Decker, Jake E., Ou, Jiafu , Choudhary, Gaurav , Gazmuri, Raúl J. , Schmader, Kenneth E. , Vaughan, Camille P. , Ambrosius, Walter T. , Williamson, Jeff D. , Johnson, Kimberly S. , Espinoza, Sara , Markland, Alayne D. , Bazzano, Lydia , Benziger, Catherine P , Shapiro, Michael D , Kistler, Christine E , Gill, Thomas M , Newby, L Kristin , Cicek, Mine S , Ou, Jiafu , Gazmuri, Raúl J , Vaughan, Camille P , Supiano, Mark A , Shah, Raj C , Alexander, Karen P , Pajewski, Nicholas M , Espinoza, Sara , Jones, W. Schuyler , Orkaby, Ariela R. , Shapiro, Michael D. , Polonsky, Tamar S. , Chamberlain, Alanna M. , Forman, Daniel E. , Knowlton, Kirk U. , Gill, Thomas M. , Hammill, Bradley G. , Rubinstein, Jack , Roumie, Christianne L. , Effron, Mark B , Cooper‐DeHoff, Rhonda M. , Supiano, Mark A. , Shah, Raj C. , Whittle, Jeff , Hernandez, Adrian F. , Alexander, Karen P.

Journal of the American Geriatrics Society | April 21, 2023 | Volume: 71 | Issue: 6 | Pages: 1701-1713

10.1111/jgs.18312 | PMID 37082807 Get It

Abstract Whether initiation of statins could increase survival free of dementia and disability in adults aged ≥75 years is unknown. PREVENTABLE, a double‐blind, placebo‐controlled randomized pragmatic clinical trial, will compare high‐intensity statin therapy (atorvastatin 40 mg) with placebo in 20,000 community‐dwelling adults aged ≥75 years without cardiovascular disease, disability, or dementia at baseline. Exclusion criteria include statin use in the prior year or for >5 years and inability to take a statin. Potential participants are identified using computable phenotypes derived from the electronic health record and local referrals from the community. Participants will undergo baseline cognitive testing, with physical testing and a blinded lipid panel if feasible. Cognitive testing and disability screening will be conducted annually. Multiple data sources will be queried for cardiovascular events, dementia, and disability; survival is site‐reported and supplemented by a National Death Index search. The primary outcome is survival free of new dementia or persisting disability. Co‐secondary outcomes are a composite of cardiovascular death, hospitalization for unstable angina or myocardial infarction, heart failure, stroke, or coronary revascularization; and a composite of mild cognitive impairment or dementia. Ancillary studies will offer mechanistic insights into the effects of statins on key outcomes. Biorepository samples are obtained and stored for future study. These results will inform the benefit of statins for increasing survival free of dementia and disability among older adults. This is a pioneering pragmatic study testing important questions with low participant burden to align with the needs of the growing population of older adults.
Revolutionizing Chronic Kidney Disease Management with Machine Learning and Artificial Intelligence
Krisanapan, Pajaree , Tangpanithandee, Supawit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Pattharanitima, Pattharawin , Cheungpasitporn, Wisit , Tangpanithandee, Supawit , Krisanapan, Pajaree , Thongprayoon, Charat

Journal of Clinical Medicine | April 21, 2023 | Volume: 12 | Issue: 8 | Pages: 3018

10.3390/jcm12083018 | PMID 37109354 Get It

Chronic kidney disease (CKD) poses a significant public health challenge, affecting approximately 11% to 13% of the global population [...]
Vitamin D in Diabetes: Uncovering the Sunshine Hormone’s Role in Glucose Metabolism and Beyond
Wu, Jie , Atkins, Annette R. , Downes, Michael , Wei, Zong

Nutrients | April 21, 2023 | Volume: 15 | Issue: 8 | Pages: 1997

10.3390/nu15081997 | PMID 37111216 Get It

Over the last decades, epidemiology and functional studies have started to reveal a pivotal role of vitamin D in both type 1 and type 2 diabetes pathogenesis. Acting through the vitamin D receptor (VDR), vitamin D regulates insulin secretion in pancreatic islets and insulin sensitivity in multiple peripheral metabolic organs. In vitro studies and both T1D and T2D animal models showed that vitamin D can improve glucose homeostasis by enhancing insulin secretion, reducing inflammation, reducing autoimmunity, preserving beta cell mass, and sensitizing insulin action. Conversely, vitamin D deficiency has been shown relevant in increasing T1D and T2D incidence. While clinical trials testing the hypothesis that vitamin D improves glycemia in T2D have shown conflicting results, subgroup and meta-analyses support the idea that raising serum vitamin D levels may reduce the progression from prediabetes to T2D. In this review, we summarize current knowledge on the molecular mechanisms of vitamin D in insulin secretion, insulin sensitivity, and immunity, as well as the observational and interventional human studies investigating the use of vitamin D as a treatment for diabetes.
Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma
Cole, Kristina A. , Ijaz, Heba, Surrey, Lea F. , Santi, Mariarita , Liu, Xiaowei , Voss, Stephan D. , Fox, Elizabeth , Weigel, Brenda J. , Minard, Charles G. , Maris, John M. , Reid, Joel M.

Cancer | April 20, 2023 | Volume: 129 | Issue: 14 | Pages: 2245-2255

10.1002/cncr.34786 | PMID 37081608 Get It

AbstractBackgroundInhibition of the WEE1 kinase by adavosertib (AZD1775) potentiates replicative stress from genomic instability or chemotherapy. This study reports the pediatric solid tumor phase 2 results of the ADVL1312 trial combining irinotecan and adavosertib.MethodsPediatric patients with recurrent neuroblastoma (part B), medulloblastoma/central nervous system embryonal tumors (part C), or rhabdomyosarcoma (part D) were treated with irinotecan and adavosertib orally for 5 days every 21 days. The combination was considered effective if there were at least three of 20 responses in parts B and D or six of 19 responses in part C. Tumor tissue was analyzed for alternative lengthening of telomeres and ATRX. Patient's prior tumor genomic analyses were provided.ResultsThe 20 patients with neuroblastoma (part B) had a median of three prior regimens and 95% had a history of prior irinotecan. There were three objective responses (9, 11, and 18 cycles) meeting the protocol defined efficacy end point. Two of the three patients with objective responses had tumors with alternative lengthening of telomeres. One patient with pineoblastoma had a partial response (11 cycles), but parts C and D did not meet the protocol defined efficacy end point. The combination was well tolerated and there were no dose limiting toxicities at cycle 1 or beyond in any parts of ADVL1312 at the recommended phase 2 dose.ConclusionThis is first phase 2 clinical trial of adavosertib in pediatrics and the first with irinotecan. The combination may be of sufficient activity to consider further study of adavosertib in neuroblastoma.
Knotless Arthroscopic Dorsal Scapholunate Capsulodesis: A Simplified Technique
Kakar, Sanjeev , Kalapos, Robert , Kakar, Sanjeev

Journal of Wrist Surgery | April 20, 2023 | Volume: 13 | Issue: 05 | Pages: 463-468

10.1055/s-0043-1768134 | PMID 39296662 Get It

Abstract Background Partial dorsal tears of the scapholunate ligament are a common soft-tissue injury in the wrist. These injuries have been a challenging problem and have gone through evolutionary changes over time from different open to arthroscopic techniques. Objectives This study describes a knotless arthroscopic dorsal scapholunate (SL) capsulodesis technique using both the radiocarpal and midcarpal joint portals, indicated for acute or chronic reducible scapholunate instability. Methods Using arthroscopy, we pierce the dorsal capsule on both sides of the dorsal torn remains of the SL ligament with two 18-gauge needles, one loaded with a 2–0 suture and the other with a nitinol wire loop. The 2–0 suture is weaved through the nitinol loop to create a knotless mattress stitch within the midcarpal joint and reduce the torn SL ligament. Results In this article, we present the outcomes of a patient treated with this arthroscopic inside knotless technique in treating scapholunate instability. Conclusions This knotless arthroscopic scapholunate capsulodesis technique provides a simple method to performing an arthroscopic dorsal capsulodesis.
Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH
Li, Jiahui , Kalutkiewicz, Kyle, Mounajjed, Taofic, Therneau, Terry M. , Venkatesh, Sudhakar K. , Glaser, Kevin J. , Hoodeshenas, Safa , Shah, Vijay H. , Zhu, Zheng, Kalutkiewicz, Kyle J, Venkatesh, Sudhakar K , Sui, Yi , Manduca, A , Ehman, Richard , Allen, Alina M , Li, Jiahui , Lü, Xin , Zhu, Zheng Hong , Sui, Yi, Manduca, Armando , Ehman, Richard L. , Allen, Alina M. , Yin, Meng

Hepatology | April 20, 2023 | Volume: 78 | Issue: 4 | Pages: 1200-1208

10.1097/hep.0000000000000417 | PMID 37080558 Get It

Background and Aims: The presence of at-risk NASH is associated with an increased risk of cirrhosis and complications. Therefore, noninvasive identification of at-risk NASH with an accurate biomarker is a critical need for pharmacologic therapy. We aim to explore the performance of several magnetic resonance (MR)-based imaging parameters in diagnosing at-risk NASH. Approach and Results: This prospective clinical trial (NCT02565446) includes 104 paired MR examinations and liver biopsies performed in patients with suspected or diagnosed NAFLD. Magnetic resonance elastography-assessed liver stiffness (LS), 6-point Dixon-derived proton density fat fraction (PDFF), and single-point saturation-recovery acquisition-calculated T1 relaxation time were explored. Among all predictors, LS showed the significantly highest accuracy in diagnosing at-risk NASH [AUCLS: 0.89 (0.82, 0.95), AUCPDFF: 0.70 (0.58, 0.81), AUCT1: 0.72 (0.61, 0.82), z-score test z >1.96 for LS vs any of others]. The optimal cutoff value of LS to identify at-risk NASH patients was 3.3 kPa (sensitivity: 79%, specificity: 82%, negative predictive value: 91%), whereas the optimal cutoff value of T1 was 850 ms (sensitivity: 75%, specificity: 63%, and negative predictive value: 87%). PDFF had the highest performance in diagnosing NASH with any fibrosis stage [AUCPDFF: 0.82 (0.72, 0.91), AUCLS: 0.73 (0.63, 0.84), AUCT1: 0.72 (0.61, 0.83), |z| <1.96 for all]. Conclusion: Magnetic resonance elastography-assessed LS alone outperformed PDFF, and T1 in identifying patients with at-risk NASH for therapeutic trials.